Last updated 2026-06-18
- Went public, Jan 1951
- Raised $400M funding round, Mar 2026
- Raised $150M funding round led by Abingworth, Apr 2024
Total raised
$908.0M
Last: 2026-03
Stage
Public
Founded
1901
Headcount
500+
HQ
Tel Aviv, Israel
Sector
Health Tech & Life Sciences
About
Teva is a global pharmaceutical company that develops, produces, and markets generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients.
Headquartered in Israel, Teva has a product portfolio of more than 3,600 medicines and produces approximately 120 billion tablets and capsules a year at 70 manufacturing facilities. Teva is ranked among the leading pharmaceutical companies in the world and is active in 60 countries, with approximately 43,000 employees worldwide.
Funding history · 3 rounds · $908.0M total
2026-03
$400.0M
2024-04
$150.0M
2018-02
Q&A
- What was Teva Pharmaceuticals' most recent funding round?
- In March 2026, Teva Pharmaceuticals raised $400 million in a funding round with Blackstone.
- When did Teva Pharmaceuticals acquire Emalex Biosciences?
- Teva Pharmaceuticals acquired Emalex Biosciences in April 2026 for $900 million.
- What was a significant product approval for Teva Pharmaceuticals in March 2026?
- In March 2026, Teva Pharmaceuticals received FDA approval for its Prolia biosimilar and had its Xolair filing accepted.
- What new online resource did Teva Pharmaceuticals launch in April 2026?
- In April 2026, Teva Pharmaceuticals launched Home Ground™ Schizophrenia Community, an online resource hub for individuals with schizophrenia and their care partners.
- What was a key development for Teva Pharmaceuticals' schizophrenia treatment in February 2026?
- In February 2026, the U.S. FDA accepted Teva Pharmaceuticals' New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the once-monthly treatment of schizophrenia in adults.
- What strategic agreement did Teva Pharmaceuticals enter into with Royalty Pharma in January 2026?
- In January 2026, Teva Pharmaceuticals and Royalty Pharma entered an agreement to accelerate the development of a potential treatment for Vitiligo.
- What was a notable financial rating upgrade for Teva Pharmaceuticals in December 2025?
- In December 2025, S&P Global Ratings upgraded Teva Pharmaceuticals to ‘BB+’ due to strong execution of its Pivot to Growth Strategy, and Moody's Ratings Agency revised its outlook to Positive.
- What new data did Teva Pharmaceuticals present in June 2026 regarding Huntington's Disease?
- In June 2026, Teva Pharmaceuticals presented new data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets, showing patient- and caregiver-reported improvements in Huntington's Disease Chorea.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2CB2B
Highlights
Patents
Tags
respiratorywomen-healthneurologyoncologygeneric-drugsbiological-therapypharmaceuticalspatientsbiopharmaceuticalnanotechnologychronic-patientsdrug-deliverydoctorsmedical-cannabis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | tevapharm.com |
|---|---|
| linkedin.com/company/5239 |
Identifiers & details
| Legal name | Teva Pharmaceutical Industries Ltd. |
|---|---|
| Founded | 1901-1 |
| Employees (exact) | 500 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Emalex Biosciences | 2026-04 | $900.0M |
| Anda | 2016-10 | |
| Actavis | 2016-08 | $40.0B |
| Rimsa | 2015-10 | $2.3B |
| Gecko Health Innovations | 2015-09 | |
| Auspex Pharmaceuticals | 2015-03 | $3.5B |
| Labrys Biologics | 2014-06 | $825.0M |
| NuPathe | 2014-01 | $144.0M |
| MicroDose Therapeutx | 2013-06 | $165.0M |
| Cephalon | 2011-05 | $6.8B |
| Barr Pharmaceuticals | 2008-07 | $7.5B |
| Copley Pharmaceutical | 1999-08 | $220.0M |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 1982-01 | ||||
| 1951-01 |